By Fineline Cube 
WuXi AppTec Co., Ltd. (SHA: 603259, HKG: 2359) released its first-half 2026 (H1’2026) financial results.
Financial Performance Summary
| Metric | H1 2026 | YOY Change |
|---|---|---|
| Total Revenue | RMB 28.90 billion | +38.93% |
| Total Profit | RMB 13.52 billion | +36.44% |
Business Segment Breakdown
- WuXi Chemistry: Revenue of RMB 24.99 billion (+53.3% YOY)
- WuXi Testing: Revenue of RMB 2.48 billion (+31.5% YOY)
- WuXi Biology: Revenue of RMB 1.39 billion (+11.2% YOY)
Revised Full-Year 2026 Guidance
The company has comprehensively upgraded its full-year 2026 guidance:
- Previous Revenue Guidance: RMB 51.3–53.0 billion (18%–22% YOY growth for continuing operations)
- New Revenue Guidance: RMB 58.5–60.5 billion (35%–39% YOY growth for continuing operations)
- Revenue Increase: Guidance raised by approximately RMB 7.2 billion at midpoint
Strategic Significance
This exceptional performance demonstrates WuXi AppTec’s continued leadership as a global open-access R&D capability platform in the life sciences industry. The strong growth across all business segments reflects robust demand from both global biopharmaceutical companies and emerging biotech innovators.
WuXi Chemistry’s outstanding 53.3% growth highlights the success of the company’s integrated CRDMO (Contract Research, Development and Manufacturing Organization) strategy, while WuXi Testing and WuXi Biology continue to show solid double-digit growth momentum.
Market Context & Competitive Positioning
- Global CRO/CDMO Market: Experiencing sustained growth driven by increasing drug development complexity and outsourcing trends
- Competitive Advantage: Integrated platform approach enables seamless “Follow-the-Molecule” strategy from discovery through commercial manufacturing
- Capacity Expansion: Recent investments in China, US, and Europe now fully operational to meet growing client demand
- Order Backlog: Remains at record levels, providing strong revenue visibility for remainder of 2026 and into 2027
Company Statement
“We are extremely pleased with our first-half results, which validate our unique business model and strategic positioning,” said Dr. Ge Li, Chairman and CEO of WuXi AppTec. “Our integrated platform approach continues to deliver significant value to our global partners, enabling them to accelerate their drug development timelines while reducing costs. The decision to raise our full-year guidance demonstrates our confidence in sustained demand and our ability to execute on our long-term growth strategy.”
Forward-Looking Statements
This brief contains forward-looking statements regarding financial performance, growth expectations, and business outlook. Actual results may differ due to market dynamics, competitive pressures, regulatory developments, and other risk factors.-Fineline Info & Tech